ATE346085T1 - Inhibitoren des interleukin-1-beta konvertierenden enzyms - Google Patents
Inhibitoren des interleukin-1-beta konvertierenden enzymsInfo
- Publication number
- ATE346085T1 ATE346085T1 AT97949771T AT97949771T ATE346085T1 AT E346085 T1 ATE346085 T1 AT E346085T1 AT 97949771 T AT97949771 T AT 97949771T AT 97949771 T AT97949771 T AT 97949771T AT E346085 T1 ATE346085 T1 AT E346085T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- gamma
- interleukin
- diseases
- relates
- Prior art date
Links
- 108090000426 Caspase-1 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 102100037850 Interferon gamma Human genes 0.000 abstract 4
- 108010074328 Interferon-gamma Proteins 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102000000589 Interleukin-1 Human genes 0.000 abstract 2
- 108010002352 Interleukin-1 Proteins 0.000 abstract 2
- 102000003810 Interleukin-18 Human genes 0.000 abstract 2
- 108090000171 Interleukin-18 Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 229960003130 interferon gamma Drugs 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000001066 destructive effect Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3212996P | 1996-12-06 | 1996-12-06 | |
| US4193897P | 1997-04-04 | 1997-04-04 | |
| US5079697P | 1997-06-26 | 1997-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE346085T1 true ATE346085T1 (de) | 2006-12-15 |
Family
ID=27364031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97949771T ATE346085T1 (de) | 1996-12-06 | 1997-12-05 | Inhibitoren des interleukin-1-beta konvertierenden enzyms |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6350741B1 (de) |
| EP (1) | EP0942925B1 (de) |
| JP (1) | JP4094066B2 (de) |
| AT (1) | ATE346085T1 (de) |
| AU (1) | AU7624798A (de) |
| CA (1) | CA2274250A1 (de) |
| DE (1) | DE69736984T2 (de) |
| WO (1) | WO1998024804A2 (de) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
| IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
| FR2781483A1 (fr) * | 1998-07-21 | 2000-01-28 | Hoechst Marion Roussel Inc | Derives de thioazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicament et compositions pharmaceutiques les renfermant |
| US7015212B1 (en) | 1999-05-12 | 2006-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Thiazepine inhibitors of HIV-1 integrase |
| DK1355668T3 (da) * | 2001-01-29 | 2008-05-05 | Serono Lab | Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom |
| WO2002066063A1 (en) * | 2001-02-23 | 2002-08-29 | Nippon Organon K.K. | Remedies for metabolic bone diseases |
| US7001899B2 (en) * | 2002-06-10 | 2006-02-21 | The Procter & Gamble Company | Interleukin converting enzyme inhibitors |
| US20040151704A1 (en) | 2002-06-28 | 2004-08-05 | Xcyte Therapies, Inc. | Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| CN1835769B (zh) * | 2002-12-30 | 2011-06-29 | 比奥根艾迪克Ma公司 | Kim-1拮抗剂及其在免疫系统调节中的应用 |
| US20060128696A1 (en) * | 2004-05-15 | 2006-06-15 | Annamaria Vezzani | Treating seizures using ice inhibitors |
| JP2008520744A (ja) * | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
| BRPI0608254A2 (pt) | 2005-03-02 | 2009-12-08 | Biogen Idec Inc | anticorpos kim-1 para o tratamento de condições mediadas por th2 |
| AU2007347115A1 (en) | 2006-04-04 | 2008-10-23 | The Regents Of The University Of California | PI3 kinase antagonists |
| GB2467670B (en) * | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| DK2240451T3 (da) * | 2008-01-04 | 2017-11-20 | Intellikine Llc | Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer |
| US8193182B2 (en) * | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| US8637542B2 (en) * | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| CA2740885C (en) | 2008-10-16 | 2018-04-03 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| BRPI0914035A2 (pt) | 2008-10-17 | 2015-11-03 | Koninkl Philips Electronics Nv | ventilador e método para ventilar um paciente usando um ventilador |
| US8476282B2 (en) * | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| EP2427195B1 (de) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclische verbindungen und ihre verwendung |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| CN103269586B (zh) | 2010-10-26 | 2015-07-15 | 普雷西迪奥制药公司 | 丙型肝炎病毒抑制剂 |
| AU2011326427B2 (en) | 2010-11-10 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| PE20180318A1 (es) | 2011-01-10 | 2018-02-09 | Infinity Pharmaceuticals Inc | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas |
| JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン， エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
| WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| WO2013012915A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
| AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
| JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| KR20150061651A (ko) | 2012-09-26 | 2015-06-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ire1의 조절 |
| LT2914296T (lt) | 2012-11-01 | 2018-09-25 | Infinity Pharmaceuticals, Inc. | Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| WO2015051244A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN103804367B (zh) * | 2014-02-28 | 2016-09-14 | 天津药物研究院 | 苯并氮杂卓衍生物、其制备方法和用途 |
| EP3119397B1 (de) | 2014-03-19 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclische verbindungen zur verwendung bei der behandlung von pi3k-gamma-vermittelten erkrankungen |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG10201913880XA (en) | 2015-07-02 | 2020-03-30 | Hoffmann La Roche | Bicyclic lactams and methods of use thereof |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| CN118994191A (zh) | 2016-02-05 | 2024-11-22 | 戴纳立制药公司 | 受体相互作用蛋白激酶1的抑制剂 |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| UA125216C2 (uk) | 2016-06-24 | 2022-02-02 | Інфініті Фармасьютікалз, Інк. | Комбінована терапія |
| WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
| HRP20220636T1 (hr) | 2016-12-09 | 2022-07-22 | Denali Therapeutics Inc. | Spojevi korisni kao inhibitori ripk1 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| EP3781571B1 (de) | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-2-carboxamid-derivate und ähnliche verbindungen als rip1 kinase inhibitoren zur behandlung von z.b. reizdarmsyndrom (rds) |
| AU2023206890A1 (en) | 2022-01-12 | 2024-08-22 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| AU6909194A (en) * | 1993-05-14 | 1994-12-12 | Board Of Regents, The University Of Texas System | Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole |
| US5580979A (en) * | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| JPH09295996A (ja) * | 1996-03-06 | 1997-11-18 | Takeda Chem Ind Ltd | システインプロテアーゼ阻害化合物 |
-
1997
- 1997-12-05 JP JP52583898A patent/JP4094066B2/ja not_active Expired - Lifetime
- 1997-12-05 DE DE69736984T patent/DE69736984T2/de not_active Expired - Lifetime
- 1997-12-05 AT AT97949771T patent/ATE346085T1/de not_active IP Right Cessation
- 1997-12-05 WO PCT/US1997/022355 patent/WO1998024804A2/en not_active Ceased
- 1997-12-05 CA CA002274250A patent/CA2274250A1/en not_active Abandoned
- 1997-12-05 EP EP97949771A patent/EP0942925B1/de not_active Expired - Lifetime
- 1997-12-05 AU AU76247/98A patent/AU7624798A/en not_active Abandoned
-
1999
- 1999-06-04 US US09/326,494 patent/US6350741B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001506986A (ja) | 2001-05-29 |
| EP0942925B1 (de) | 2006-11-22 |
| DE69736984D1 (de) | 2007-01-04 |
| US6350741B1 (en) | 2002-02-26 |
| AU7624798A (en) | 1998-06-29 |
| DE69736984T2 (de) | 2007-09-13 |
| WO1998024804A3 (en) | 1998-09-03 |
| CA2274250A1 (en) | 1998-06-11 |
| WO1998024804A2 (en) | 1998-06-11 |
| EP0942925A2 (de) | 1999-09-22 |
| JP4094066B2 (ja) | 2008-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE346085T1 (de) | Inhibitoren des interleukin-1-beta konvertierenden enzyms | |
| BG104863A (en) | Inhibitors of caspases | |
| DE69732712D1 (de) | INHIBITOREN DES INTERLEUKIN-1beta KONVERTIERENDEN ENZYMS | |
| ATE310011T1 (de) | Inhibitoren des interleukin-1-beta konvertierenden enzyms | |
| ATE296812T1 (de) | 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms | |
| MX9805016A (es) | INHIBIDORES DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1 beta. | |
| ATE240103T1 (de) | Intermediaires des produits definitifs de glycosylation avancee et inhibition des produits age post-amadori | |
| BRPI0015533B8 (pt) | enzima alfa-l-iduronidase humana recombinante, composição farmacêutica compreendendo a mesma e método para sua purificação | |
| ATE311853T1 (de) | Verwendung von krillenzymen zur behandlung von zahnbelag | |
| BRPI9917881B8 (pt) | compostos inibidores de caspases, composição farmacêutica e uso de ditos compostos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |